ERKed by LRRK2: A cell biological perspective on hereditary and sporadic Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 8, 2014, Pages 1273-1281

  Verma, Manish ^a   Steer, Erin K ^a   Chu, Charleen T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; Cytoskeleton; LRRK2; MAPK; Mitophagy; Parkinson disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; WNT PROTEIN;

AUTOPHAGOSOME; AUTOPHAGY; CALCIUM HOMEOSTASIS; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CYTOLOGY; DIFFUSE LEWY BODY DISEASE; GENE INTERACTION; GENE MUTATION; GENETIC DISORDER; HUMAN; MITOCHONDRIAL DYNAMICS; NERVE CELL PLASTICITY; NERVE DEGENERATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SUBSTANTIA NIGRA; WNT SIGNALING PATHWAY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOSOME; MICROTUBULE; MITOCHONDRION; NONHUMAN;

AUTOPHAGY; CYTOSKELETON; LRRK2; MAPK; MITOPHAGY; PARKINSON DISEASE;

ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MODELS, BIOLOGICAL; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; WNT SIGNALING PATHWAY;

EID: 84903318104     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.11.005     Document Type: Review

References (133)

1. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339:1044-1053.
2. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
3. Gorrell J.M., DiMonte D., Graham D. The role of the environment in Parkinson's disease. Environ. Health Perspect. 1996, 104:652-654.
4. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992, 42:1328-1335.
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
6. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 1993, 61:1191-1206.
7. Dawson T.M., Dawson V.L. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 2003, 111:145-151.
8. Bekris L.M., Mata I.F., Zabetian C.P. The genetics of Parkinson disease. J. Geriatr. Psychiatry Neurol. 2010, 23:228-242.
9. Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C., Blazquez M., Guisasola L.M., Salvador C., Ribacoba R., Martinez C., Farrer M., Alvarez V. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci. Lett. 2005, 382:309-311.
10. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 2006, 15:223-232.
11. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
12. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S., Obata F. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 2005, 57:918-921.
13. Rideout H.J., Stefanis L. The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease. Neurochem. Res. 2013, 10.1007/s11064-013-1073-5.
14. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN neurol. 2009, 1.
15. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 2002, 51:296-301.
16. Paisán-Ruíz C., Jain S., Evans E.W., Gilks W.P., Simón J., van der Brug M., López de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Martí-Massó J.F., Pérez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
17. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
18. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
19. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.-W., Savitt J.M., Waldvogel H.J., Faull R.L.M., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
20. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J., Healy D.G., Holton J.L., Revesz T., Wood N.W. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
21. Ishihara L., Gibson R.A., Warren L., Amouri R., Lyons K., Wielinski C., Hunter C., Swartz J.E., Elango R., Akkari P.A., Leppert D., Surh L., Reeves K.H., Thomas S., Ragone L., Hattori N., Pahwa R., Jankovic J., Nance M., Freeman A., Gouider-Khouja N., Kefi M., Zouari M., Ben Sassi S., Ben Yahmed S., El Euch-Fayeche G., Middleton L., Burn D.J., Watts R.L., Hentati F. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov. Disord: Off. J. Mov. Disord. Soc. 2007, 22:55-61.
22. Munhoz R.P., Wakutani Y., Marras C., Teive H.A., Raskin S., Werneck L.C., Moreno D., Sato C., Lang A.E., Rogaeva E. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. Mov. Disord.: Off. J. Mov. Disord. Soc. 2008, 23:290-294.
23. Correia Guedes L., Ferreira J.J., Rosa M.M., Coelho M., Bonifati V., Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat. Disord. 2010, 16:237-242.
24. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiology of disease 2006, 23:329-341.
25. Deng X., Dzamko N., Prescott A., Davies P., Liu Q., Yang Q., Lee J.-D., Patricelli M.P., Nomanbhoy T.K., Alessi D.R., Gray N.S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature chemical biology 2011, 7:203-205.
26. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. The Biochemical journal 2007, 405:307-317.
27. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in parkinsonian neurodegeneration?. Journal of neurochemistry 2009, 110:1514-1522.
28. Imai Y., Gehrke S., Wang H.-Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
29. Qing H., Zhang Y., Deng Y., McGeer E.G., McGeer P.L. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009, 390:1229-1234.
30. Glick D., Barth S., Macleod K.F. Autophagy: cellular and molecular mechanisms. J. Pathol. 2010, 221:3-12.
31. Singh R., Cuervo A.M. Autophagy in the cellular energetic balance. Cell Metab. 2011, 13:495-504.
32. Rabinowitz J.D., White E. Autophagy and metabolism. Science (New York, N.Y.) 2010, 330:1344-1348.
33. Cherra S.J., Dagda R.K., Chu C.T. Review: autophagy and neurodegeneration: survival at a cost?. Neuropathol. Appl. Neurobiol. 2010, 36:125-132.
34. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
35. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J.-i., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
36. Oczypok E.A., Oury T.D., Chu C.T. It's a cell-eat-cell world: autophagy and phagocytosis. Am. J. Pathol. 2013, 182:612-622.
37. Cherra S.J., Kulich S.M., Uechi G., Balasubramani M., Mountzouris J., Day B.W., Chu C.T. Regulation of the autophagy protein LC3 by phosphorylation. J. Cell Biol. 2010, 190:533-539.
38. Cherra S.J., Steer E., Gusdon A.M., Kiselyov K., Chu C.T. Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am. J. Pathol. 2013, 182:474-484.
39. Plowey E.D., Cherra S.J., Liu Y.-J., Chu C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008, 105:1048-1056.
40. Alegre-Abarrategui J., Christian H., Lufino M.M.P., Mutihac R., Venda L.L., Ansorge O., Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
41. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
42. Gómez-Suaga P., Luzón-Toro B., Churamani D., Zhang L., Bloor-Young D., Patel S., Woodman P.G., Churchill G.C., Hilfiker S. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 2012, 21:511-525.
43. Fass E., Shvets E., Degani I., Hirschberg K., Elazar Z. Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes. J. Biol. Chem. 2006, 281:36303-36316.
44. Manzoni C., Mamais A., Dihanich S., Abeti R., Soutar M.P., Plun-Favreau H., Giunti P., Tooze S.A., Bandopadhyay R., Lewis P.A. Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim. Biophys. Acta 2013, 1833:2900-2910.
45. Tong Y., Yamaguchi H., Giaime E., Boyle S., Kopan R., Kelleher R.J., Shen J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9879-9884.
46. Tong Y., Giaime E., Yamaguchi H., Ichimura T., Liu Y., Si H., Cai H., Bonventre J.V., Shen J. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol. Neurodegener. 2012, 7.
47. Ramonet D., Daher J.P.L., Lin B.M., Stafa K., Kim J., Banerjee R., Westerlund M., Pletnikova O., Glauser L., Yang L., Liu Y., Swing D.A., Beal M.F., Troncoso J.C., McCaffery J.M., Jenkins N.A., Copeland N.G., Galter D., Thomas B., Lee M.K., Dawson T.M., Dawson V.L., Moore D.J. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 2011, 6:e18568.
48. Hindle S., Afsari F., Stark M., Middleton C.A., Evans G.J.O., Sweeney S.T., Elliott C.J.H. Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy. Hum. Mol. Genet. 2013, 22:2129-2140.
49. Friedman L.G., Lachenmayer M.L., Wang J., He L., Poulose S.M., Komatsu M., Holstein G.R., Yue Z. Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain. J. Neurosci.: Off. J. Soc. Neurosci. 2012, 32:7585-7593.
50. Kirschner M., Mitchison T. Beyond self-assembly: from microtubules to morphogenesis. Cell 1986, 45:329-342.
51. Cairns N.J., Lee V.M.-Y., Trojanowski J.Q. The cytoskeleton in neurodegenerative diseases. J. Pathol. 2004, 204:438-449.
52. McMurray C.T. Neurodegeneration: diseases of the cytoskeleton?. Cell Death Differ. 2000, 7:861-865.
53. Ren Y., Liu W., Jiang H., Jiang Q., Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 2005, 280:34105-34112.
54. Gandhi P.N., Wang X., Zhu X., Chen S.G., Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 2008, 86:1711-1720.
55. Kett L.R., Boassa D., Ho C.C.-Y., Rideout H.J., Hu J., Terada M., Ellisman M., Dauer W.T. LRRK2 Parkinson disease mutations enhance its microtubule association. Hum. Mol. Genet. 2012, 21:890-899.
56. Melrose H.L., Dachsel J.C., Behrouz B., Lincoln S.J., Yue M., Hinkle K.M., Kent C.B., Korvatska E., Taylor J.P., Witten L., Liang Y.Q., Beevers J.E., Boules M., Dugger B.N., Serna V.A., Gaukhman A., Yu X., Castanedes-Casey M., Braithwaite A.T., Ogholikhan S., Yu N., Bass D., Tyndall G., Schellenberg G.D., Dickson D.W., Janus C., Farrer M.J. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
57. Ujiie S., Hatano T., Kubo S.-I., Imai S., Sato S., Uchihara T., Yagishita S., Hasegawa K., Kowa H., Sakai F., Hattori N. LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat. Disord. 2012, 18:819-823.
58. Kawakami F., Yabata T., Ohta E., Maekawa T., Shimada N., Suzuki M., Maruyama H., Ichikawa T., Obata F. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PloS ONE 2012, 7:e30834.
59. Lin C.-H., Tsai P.-I., Wu R.-M., Chien C.-T. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. J. Neurosci.: Off. J. Soc. Neurosci. 2010, 30:13138-13149.
60. Gross S.R., Kinzy T.G. Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat. Struct. Mol. Biol. 2005, 12:772-778.
61. Shiina N., Gotoh Y., Kubomura N., Iwamatsu A., Nishida E. Microtubule severing by elongation factor 1 alpha. Science (New York, N.Y.) 1994, 266:282-285.
62. Gillardon F. Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Neuroscience 2009, 163:533-539.
63. Meixner A., Boldt K., Van Troys M., Askenazi M., Gloeckner C.J., Bauer M., Marto J.A., Ampe C., Kinkl N., Ueffing M. A QUICK screen for Lrrk2 interaction partners - leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol. Cell Proteomics: MCP 2011, 10. (M110.001172).
64. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.-L., Long C.-X., Lobbestael E., Baekelandt V., Taymans J.-M., Sun L., Cai H. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci.: Off. J. Soc. Neurosci. 2009, 29:13971-13980.
65. Nichols R.J., Dzamko N., Hutti J.E., Cantley L.C., Deak M., Moran J., Bamborough P., Reith A.D., Alessi D.R. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 2009, 424:47-60.
66. Tain L.S., Mortiboys H., Tao R.N., Ziviani E., Bandmann O., Whitworth A.J. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 2009, 12:1129-1135.
67. Kumar A., Greggio E., Beilina A., Kaganovich A., Chan D., Taymans J.-M., Wolozin B., Cookson M.R. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PloS ONE 2010, 5:e8730.
68. Trancikova A., Mamais A., Webber P.J., Stafa K., Tsika E., Glauser L., West A.B., Bandopadhyay R., Moore D.J. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PloS ONE 2012, 7:e47784.
69. Venderova K., Kabbach G., Abdel-Messih E., Zhang Y., Parks R.J., Imai Y., Gehrke S., Ngsee J., Lavoie M.J., Slack R.S., Rao Y., Zhang Z., Lu B., Haque M.E., Park D.S. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:4390-4404.
70. Papkovskaia T.D., Chau K.-Y., Inesta-Vaquera F., Papkovsky D.B., Healy D.G., Nishio K., Staddon J., Duchen M.R., Hardy J., Schapira A.H.V., Cooper J.M. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum. Mol. Genet. 2012, 21:4201-4213.
71. Mortiboys H., Johansen K.K., Aasly J.O., Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010, 75:2017-2020.
72. Dagda R.K., Gusdon A.M., Pien I., Strack S., Green S., Li C., Van Houten B., Cherra S.J., Chu C.T. Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease. Cell Death Differ. 2011, 18:1914-1923.
73. Sandebring A., Thomas K.J., Beilina A., van der Brug M., Cleland M.M., Ahmad R., Miller D.W., Zambrano I., Cowburn R.F., Behbahani H., Cedazo-Mínguez A., Cookson M.R. Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PloS ONE 2009, 4:e5701.
74. Niu J., Yu M., Wang C., Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J. Neurochem. 2012, 122:650-658.
75. Wang X., Yan M.H., Fujioka H., Liu J., Wilson-Delfosse A., Chen S.G., Perry G., Casadesus G., Zhu X. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 2012, 21:1931-1944.
76. Dagda R.K., Cherra S.J., Kulich S.M., Tandon A., Park D., Chu C.T. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009, 284:13843-13855.
77. Narendra D.P., Jin S.M., Tanaka A., Suen D.-F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8:e1000298.
78. Gandhi S., Wood-Kaczmar A., Yao Z., Plun-Favreau H., Deas E., Klupsch K., Downward J., Latchman D.S., Tabrizi S.J., Wood N.W., Duchen M.R., Abramov A.Y. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 2009, 33:627-638.
79. Heeman B., Van den Haute C., Aelvoet S.-A., Valsecchi F., Rodenburg R.J., Reumers V., Debyser Z., Callewaert G., Koopman W.J.H., Willems P.H.G.M., Baekelandt V. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J. Cell Sci. 2011, 124:1115-1125.
80. Marongiu R., Spencer B., Crews L., Adame A., Patrick C., Trejo M., Dallapiccola B., Valente E.M., Masliah E. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J. Neurochem. 2009, 108:1561-1574.
81. Plowey E.D., Chu C.T. Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy?. Neurobiol. Dis. 2011, 43(1):60-67. Epub 2010 Oct 20. 10.1016/j.nbd.2010.10.011.
82. Lee S., Liu H.P., Lin W.Y., Guo H., Lu B. LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J. Neurosci.: Off. J. Soc. Neurosci. 2010, 30:16959-16969.
83. Piccoli G., Condliffe S.B., Bauer M., Giesert F., Boldt K., De Astis S., Meixner A., Sarioglu H., Vogt-Weisenhorn D.M., Wurst W., Gloeckner C.J., Matteoli M., Sala C., Ueffing M. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci.: Off. J. Soc. Neurosci. 2011, 31:2225-2237.
84. MacLeod D.A., Rhinn H., Kuwahara T., Zolin A., Di Paolo G., McCabe B.D., Marder K.S., Honig L.S., Clark L.N., Small S.A., Abeliovich A. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 2013, 77:425-439.
85. Shin N., Jeong H., Kwon J., Heo H.Y., Kwon J.J., Yun H.J., Kim C.H., Han B.S., Tong Y., Shen J., Hatano T., Hattori N., Kim K.S., Chang S., Seol W. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 2008, 314:2055-2065.
86. Xiong Y., Coombes C.E., Kilaru A., Li X., Gitler A.D., Bowers W.J., Dawson V.L., Dawson T.M., Moore D.J. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 2010, 6:e1000902.
87. Matta S., Van Kolen K., da Cunha R., van den Bogaart G., Mandemakers W., Miskiewicz K., De Bock P.J., Morais V.A., Vilain S., Haddad D., Delbroek L., Swerts J., Chavez-Gutierrez L., Esposito G., Daneels G., Karran E., Holt M., Gevaert K., Moechars D.W., De Strooper B., Verstreken P. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
88. Chu C.T. Autophagic stress in neuronal injury and disease. J. Neuropathol. Exp. Neurol. 2006, 65:423-432.
89. Li G., Pleasure S.J. Morphogenesis of the dentate gyrus: what we are learning from mouse mutants. Dev. Neurosci. 2005, 27:93-99.
90. Ciani L., Salinas P.C. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat. Rev. Neurosci. 2005, 6:351-362.
91. Buechling T., Boutros M. Wnt signaling signaling at and above the receptor level. Curr. Top. Dev. Biol. 2011, 97:21-53.
92. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Gene Dev. 1997, 11:3286-3305.
93. Polakis P. Wnt signaling and cancer. Gene Dev. 2000, 14:1837-1851.
94. Castelo-Branco G., Wagner J., Rodriguez F.J., Kele J., Sousa K., Rawal N., Pasolli H.A., Fuchs E., Kitajewski J., Arenas E. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12747-12752.
95. Parish C.L., Castelo-Branco G., Rawal N., Tonnesen J., Sorensen A.T., Salto C., Kokaia M., Lindvall O., Arenas E. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J. Clin. Invest. 2008, 118:149-160.
96. Andersson E.R., Saltó C., Villaescusa J.C., Cajanek L., Yang S., Bryjova L., Nagy I.I., Vainio S.J., Ramirez C., Bryja V., Arenas E. Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E602-E610.
97. Kitagawa H., Ray W.J., Glantschnig H., Nantermet P.V., Yu Y., Leu C.-T., Harada S.-i., Kato S., Freedman L.P. A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. Mol. Cell. Biol. 2007, 27:7486-7496.
98. Ohnuki T., Nakamura A., Okuyama S., Nakamura S. Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease. Brain Res. 2010, 1346:26-42.
99. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M.C., Cossetti C., D'Adamo P., Zardini E., Andreoni L., Ihekwaba A.E.C., Serra P.A., Franciotta D., Martino G., Pluchino S., Marchetti B. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol. Dis. 2011, 41:508-527.
100. Gollamudi S., Johri A., Calingasan N.Y., Yang L., Elemento O., Beal M.F. Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PloS ONE 2012, 7:e36191.
101. Dun Y., Li G., Yang Y., Xiong Z., Feng M., Wang M., Zhang Y., Xiang J., Ma R. Inhibition of the canonical Wnt pathway by Dickkopf-1 contributes to the neurodegeneration in 6-OHDA-lesioned rats. Neurosci. Lett. 2012, 525:83-88.
102. Wei L., Sun C., Lei M., Li G., Yi L., Luo F., Li Y., Ding L., Liu Z., Li S., Xu P. Activation of Wnt/β-catenin pathway by exogenous Wnt1 protects SH-SY5Y cells against 6-hydroxydopamine toxicity. J. Mol. Neurosci.:MN 2013, 49:105-115.
103. Häbig K., Walter M., Poths S., Riess O., Bonin M. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 2008, 9:83-94.
104. Ferree A., Guillily M., Li H., Smith K., Takashima A., Squillace R., Weigele M., Collins J.J., Wolozin B. Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener. Dis. 2012, 10:238-241.
105. Sancho R.M., Law B.M.H., Harvey K. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum. Mol. Genet. 2009, 18:3955-3968.
106. Berwick D.C., Harvey K. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum. Mol. Genet. 2012, 21:4966-4979.
107. Luttrell L.M. 'Location, location, location': activation and targeting of MAP kinases by G protein-coupled receptors. J. Mol. Endocrinol. 2003, 30:117-126.
108. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (New York, N.Y.) 1995, 270:1326-1331.
109. Hsu C.H., Chan D., Greggio E., Saha S., Guillily M.D., Ferree A., Raghavan K., Shen G.C., Segal L., Ryu H., Cookson M.R., Wolozin B. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem. 2010, 112:1593-1604.
110. Gloeckner C.J., Schumacher A., Boldt K., Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 2009, 109:959-968.
111. Luo Y., DeFranco D.B. Opposing roles for ERK1/2 in neuronal oxidative toxicity: distinct mechanisms of ERK1/2 action at early versus late phases of oxidative stress. J. Biol. Chem. 2006, 281:16436-16442.
112. Gómez-Santos C., Ferrer I., Reiriz J., Viñals F., Barrachina M., Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 2002, 935:32-39.
113. Kulich S.M., Chu C.T. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 2001, 77:1058-1066.
114. Zhu J.-H., Horbinski C., Guo F., Watkins S., Uchiyama Y., Chu C.T. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol. 2007, 170:75-86.
115. Kulich S.M., Horbinski C., Patel M., Chu C.T. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic. Biol. Med. 2007, 43:372-383.
116. Zhu J.-H., Kulich S.M., Oury T.D., Chu C.T. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am. J. Pathol. 2002, 161:2087-2098.
117. Ferrer I., Barrachina M., Tolnay M., Rey M.J., Vidal N., Carmona M., Blanco R., Puig B. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Brain Pathol. (Zurich, Switzerland) 2003, 13:62-78.
118. Zhu J.-H., Guo F., Shelburne J., Watkins S., Chu C.T. Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol. (Zurich, Switzerland) 2003, 13:473-481.
119. Dagda R.K., Zhu J., Kulich S.M., Chu C.T. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 2008, 4:770-782.
120. Zhu J.H., Gusdon A.M., Cimen H., Van Houten B., Koc E., Chu C.T. Impaired mitochondrial biogenesis contributes to depletion of functional mitochondria in chronic MPP+ toxicity: dual roles for ERK1/2. Cell Death Dis. 2012, 3:e312.
121. Chu C.T., Levinthal D.J., Kulich S.M., Chalovich E.M., DeFranco D.B. Oxidative neuronal injury. The dark side of ERK1/2. Eur. J. Biochem./FEBS 2004, 271:2060-2066.
122. de Bernardo S., Canals S., Casarejos M.J., Solano R.M., Menendez J., Mena M.A. Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures. J. Neurochem. 2004, 91:667-682.
123. Kulich S.M., Chu C.T. Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity. J. Biosci. 2003, 28:83-89.
124. Canals S., Casarejos M.J., de Bernardo S., Rodríguez-Martín E., Mena M.A. Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase. J. Biol. Chem. 2003, 278:21542-21549.
125. Wiegert J.S., Bading H. Activity-dependent calcium signaling and ERK-MAP kinases in neurons: a link to structural plasticity of the nucleus and gene transcription regulation. Cell Calcium 2011, 49:296-305.
126. White L.R., Toft M., Kvam S.N., Farrer M.J., Aasly J.O. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J. Neurosci. Res. 2007, 85:1288-1294.
127. Liou A.K.F., Leak R.K., Li L., Zigmond M.J. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol. Dis. 2008, 32:116-124.
128. Heo H.Y., Park J.-M., Kim C.-H., Han B.S., Kim K.-S., Seol W. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp. Cell Res. 2010, 316:649-656.
129. Carballo-Carbajal I., Weber-Endress S., Rovelli G., Chan D., Wolozin B., Klein C.L., Patenge N., Gasser T., Kahle P.J. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell. Signal. 2010, 22:821-827.
130. Bravo-San Pedro J.M., Niso-Santano M., Gómez-Sánchez R., Pizarro-Estrella E., Aiastui-Pujana A., Gorostidi A., Climent V., López de Maturana R., Sanchez-Pernaute R., López de Munain A., Fuentes J.M., González-Polo R.A. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell Mol. Life Sci.: CMLS 2013, 70:121-136.
131. Reinhardt P., Schmid B., Burbulla L.F., Schöndorf D.C., Wagner L., Glatza M., Höing S., Hargus G., Heck S.A., Dhingra A., Wu G., Müller S., Brockmann K., Kluba T., Maisel M., Krüger R., Berg D., Tsytsyura Y., Thiel C.S., Psathaki O.-E., Klingauf J., Kuhlmann T., Klewin M., Müller H., Gasser T., Schöler H.R., Sterneckert J. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013, 12:354-367.
132. Chu C.T. Diversity in the regulation of autophagy and mitophagy: lessons from Parkinson's disease. Park. Dis. 2011, 2011:789431.
133. Ferrer I., Blanco R., Carmona M., Puig B., Barrachina M., Gómez C., Ambrosio S. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J. Neural Transm. (Vienna, Austria:1996) 2001, 108:1383-1396.